Concord Biotech

CONCORDBIO is in a confirmed bearish trend on daily and monthly timeframes, with the price at ₹628.00 trading below all major moving averages and the Supertrend indicator. The setup is characterized by high volatility (annualized ~45%) and significant downside momentum, evidenced by an extreme downward gap on 2026-11-04 (-46.6% return) and a subsequent weekly gap down on 2026-11-06. While the weekly Supertrend remains bullish, the daily ADX of 22.45 indicates developing but active selling pressure, contrasting with the strong monthly trend (ADX 46.4). The stock is positioned near the middle of its 20-day and 252-day ranges but at the lower end of its 50-day range. Immediate resistance lies at ₹628.62, while support is found at ₹626.47. A break below ₹626.47 would likely extend losses toward ₹606.25. Conversely, a sustained move above ₹640.23 would be required to challenge the immediate downtrend structure.

Concord Biotech is undergoing a significant corporate restructuring through a 1:1 bonus share issue, with November 4, 2026, designated as the record date. The company approved the issuance of 10.46 crore bonus shares (face value ₹1 each) by capitalizing its share premium account, with allotments scheduled for November 5. This action doubles the number of outstanding shares while proportionally adjusting the share price, leaving total investment value unchanged. On November 4, the stock appeared to fall nearly 50% due to trading platforms displaying unadjusted previous closing prices rather than the post-bonus valuation, creating a technical distortion rather than a fundamental loss.

The timing of this corporate action coincides with a period of price weakness; the stock has declined approximately 13% in 2026 and over 15% in the past month. The bonus issue was announced in September, with November 3 serving as the final cutoff for investors to hold shares in demat accounts to qualify for the allotment. While the late Rakesh Jhunjhunwala’s associates remain holders, media reports highlight the bonus as a key event for smallcap pharma investors this week, though no new operational or financial performance data was released during this seven-day window.

Concord Biotech (NSE: CONCORDBIO) has materially altered its capital structure through a bonus share issue, while the stock price has retreated from recent levels. On November 5, 2026, the company intimated the allotment of 10,46,16,204 fully paid-up bonus equity shares to eligible shareholders, executed in a 1:1 ratio based on the record date of November 4, 2026. This corporate action, approved via Board circular resolution, has doubled the company's paid-up share capital to Rs. 20,92,32,408/-, divided into an equivalent number of equity shares of Rs. 1/- each.

Market pricing reflects a shift in valuation dynamics following this event. As of the observation date of November 6, 2026, the share price stood at ₹628.00, down from a previous recorded level of ₹671.00. The bonus issuance increases the total number of outstanding shares without changing the underlying business assets or operations, which typically adjusts the per-share market value proportionally. Investors should note that the immediate post-allotment price movement indicates how the market is currently re-pricing the equity relative to the expanded share count.

Concord Biotech Limited has completed the allotment of 10,46,16,204 bonus equity shares following a 1:1 ratio approved by the Board. The record date for this corporate action was November 04, 2026, and the intimation to the exchange was filed on November 05, 2026. This allotment increases the company's paid-up share capital to Rs. 20,92,32,408, divided into an equal number of equity shares with a face value of Rs. 1/- each.

In parallel, the company disclosed the transcript of its Q2 and H1 FY27 earnings call held on October 28, 2026. Management reported that Q2 revenue reached Rs. 309.1 crore, representing a 25% year-on-year increase, while H1 revenue stood at Rs. 566.6 crore, up 26%. These filings confirm the execution of the bonus issue and provide recent operational performance metrics.

Concord Biotech’s operating trajectory shows a clear recovery in the June 2026 quarter (Q2 FY2026-27), with revenue rising 20% sequentially to ₹309 crore and net profit increasing 21% to ₹69.6 crore. This follows a significant contraction in the prior year, where full-year sales fell from ₹1,200 crore (Mar 2025) to ₹1,055 crore (Mar 2026). Despite this recent rebound, earnings quality remains under pressure; the Compounded Profit Growth over three years is just 1%, and TTM profit growth is -8%. The balance sheet reflects ongoing expansion, with Capital Work-in-Progress (CWIP) rising to ₹112 crore by Sep 2026 and total assets growing to ₹2,327 crore. However, working capital efficiency has deteriorated sharply, with the Cash Conversion Cycle widening to 492 days in Mar 2026, driven primarily by Inventory Days jumping to 483 days. While borrowings are low at ₹1 crore, cash reserves dropped to ₹7.52 crore as of Sep 2026, suggesting liquidity management is becoming tighter amid higher inventory levels.

Concord Biotech faces a deteriorating technical setup and significant price volatility, underscoring near-term downside risks. As of November 6, 2026, the stock trades at ₹628.0, reflecting a year-to-date decline of -6.0% and a substantial current drawdown of -46.5% from its peak. The daily trend is bearish, with the Supertrend indicator signaling downward pressure and moving averages (20-day and 50-day) sloping negatively (-12.14% and -15.19% respectively). Monthly trends reinforce this caution, showing a strong bearish Supertrend direction and an ADX of 46.4, indicating a robust downtrend. While the weekly timeframe shows a bullish Supertrend, the immediate daily and monthly momentum remains weak, with resistance levels clustered closely above the current price (₹628.62 to ₹656.47) and support testing lower at ₹606.25. High annualized volatility of +45.4% further amplifies risk for investors holding positions during this consolidation phase.